期刊
JOURNAL OF NEUROLOGY
卷 266, 期 6, 页码 1429-1438出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-019-09278-0
关键词
Comorbidity; Excess cost; Prognosis; Ischemic stroke; Heterogeneity
资金
- Korea Health Technology Research and Development Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HC15C1056]
- Korea National Research Foundation [2019R1A2C1003259, 2016R1C1B2016028, 2017R1A2B4003373]
- National Research Foundation of Korea [2017R1A2B4003373, 2019R1A2C1003259, 2016R1C1B2016028] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
ObjectiveComorbidities are prevalent among stroke patients. The current study assesses the variations in cost and stroke prognosis by concurrent comorbidities in patients with acute ischemic stroke.MethodsThe Charlson comorbidity index was used as the composite comorbidity level (0 none, 1 mild, 2 moderate, and 3 severe). Outcomes included modified Rankin Scale (mRS) at 3months and 1-year mortality and stroke recurrence. We utilized a multivariate log-normal model for cost, a proportional Cox hazards model for outcomes, and a decision analytic model for the excess cost per unit change in outcome probability compared with the no-comorbidity group.ResultsA total of 3605 consecutive patients were enrolled. At 3 months, the severe comorbidity group was 0.32 times less likely to have mRS2, and were 4.86 times more likely to die from stroke than the no-comorbidity group. Within 1 year, the severe comorbidity group showed 10.36 and 3.38 times higher likelihoods of death from stroke and stroke recurrence than the no-comorbidity group. The incremental cost was 4376 in 3months and 7074 USD in 1year for the severe comorbidity group, and 985 in 3months and 1265 USD in 1year for the mild comorbidity group compared to the no-comorbidity group.ConclusionThe excess cost per unit increase of a short-term good prognosis was largest for the severe comorbidity group. Patients with severe comorbidities showed poor prognosis and large health expenditure. Assessing comorbidity level is crucial for better prediction of outcomes and excess cost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据